TY  - JOUR
AU  - Gil-Gil, Miguel
AU  - Alba, Emilio
AU  - Gavila, Joaquin
AU  - de la Haba-Rodriguez, Juan
AU  - Ciruelos, Eva
AU  - Tolosa, Pablo
AU  - Candini, Daniele
AU  - Llombart-Cussac, Antonio
PY  - 2021
DO  - 10.1016/j.breast.2021.05.008
UR  - http://hdl.handle.net/10668/17956
T2  - Breast (Edinburgh, Scotland)
AB  - The use of cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) has proven to be a successful strategy in the treatment of advanced hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) breast cancer (BC), leading...
LA  - en
PB  - Churchill Livingstone
KW  - Abemaciclib
KW  - Adjuvant therapy
KW  - Cyclin-dependent kinase 4/6 inhibitors
KW  - Early breast cancer
KW  - Palbociclib
KW  - Breast neoplasms
KW  - Cyclin-dependent kinase 4
KW  - Cyclin-dependent kinase 6
KW  - Female
KW  - Humans
KW  - Protein kinase inhibitors
TI  - The role of CDK4/6 inhibitors in early breast cancer.
TY  - Research article
VL  - 58
ER  -